aTYR PHARMA INC Net Cash Provided by (Used in) Investing Activities, Continuing Operations
aTYR PHARMA INC (ATYR) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $11.41 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-15
- aTYR PHARMA INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $11.41M, a 159.47% increase year-over-year.
- aTYR PHARMA INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$3.53M, a 141.04% decline year-over-year.
- aTYR PHARMA INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$39.76M, a 694.45% decline year-over-year.
- aTYR PHARMA INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $11.25M, a 192.61% increase year-over-year.
- aTYR PHARMA INC net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$27.64M, a 182.43% decline from fiscal 2016.
- aTYR PHARMA INC net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $33.53M.
- aTYR PHARMA INC net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$71.99M.
- aTYR PHARMA INC net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$2.25M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | $11.41M 10-Q · filed 2018-05-15 | $7.88M derived: sum of 2 quarters · filed 2018-05-15 | -$31.87M derived: sum of 3 quarters · filed 2018-05-15 | -$20.62M derived: sum of 4 quarters · filed 2018-05-15 |
| 2017-12-31 | -$3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | -$43.29M derived: sum of 2 quarters · filed 2018-03-20 | -$32.04M derived: sum of 3 quarters · filed 2018-03-20 | -$27.64M 10-K · filed 2018-03-20 |
| 2017-09-30 | -$39.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | -$28.51M derived: sum of 2 quarters · filed 2017-11-14 | -$24.11M 10-Q · filed 2017-11-14 | -$15.51M derived: sum of 4 quarters · filed 2018-05-15 |
| 2017-06-30 | $11.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $15.65M 10-Q · filed 2017-08-14 | $24.25M derived: sum of 3 quarters · filed 2018-05-15 | $30.94M derived: sum of 4 quarters · filed 2018-05-15 |
| 2017-03-31 | $4.40M 10-Q · filed 2018-05-15 | $13.00M derived: sum of 2 quarters · filed 2018-05-15 | $19.69M derived: sum of 3 quarters · filed 2018-05-15 | $23.53M derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $8.60M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | $15.29M derived: sum of 2 quarters · filed 2018-03-20 | $19.14M derived: sum of 3 quarters · filed 2018-03-20 | $33.53M 10-K · filed 2018-03-20 |
| 2016-09-30 | $6.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $10.53M derived: sum of 2 quarters · filed 2017-11-14 | $24.93M 10-Q · filed 2017-11-14 | $28.83M derived: sum of 4 quarters · filed 2018-03-20 |
| 2016-06-30 | $3.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $18.24M 10-Q · filed 2017-08-14 | $22.14M derived: sum of 3 quarters · filed 2018-03-20 | $29.38M derived: sum of 4 quarters · filed 2018-03-20 |
| 2016-03-31 | $14.39M 10-Q · filed 2017-05-11 | $18.30M derived: sum of 2 quarters · filed 2018-03-20 | $25.53M derived: sum of 3 quarters · filed 2018-03-20 | -$59.43M derived: sum of 4 quarters · filed 2018-03-20 |
| 2015-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | $11.14M derived: sum of 2 quarters · filed 2018-03-20 | -$73.82M derived: sum of 3 quarters · filed 2018-03-20 | -$71.99M 10-K · filed 2018-03-20 |
| 2015-09-30 | $7.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$77.72M derived: sum of 2 quarters · filed 2016-11-14 | -$75.90M 10-Q · filed 2016-11-14 | -$73.15M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | -$84.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | -$83.14M 10-Q · filed 2016-08-10 | -$80.39M derived: sum of 3 quarters · filed 2017-03-16 | -$79.74M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-03-31 | $1.83M 10-Q · filed 2016-05-11 | $4.58M derived: sum of 2 quarters · filed 2017-03-16 | $5.23M derived: sum of 3 quarters · filed 2017-03-16 | $5.19M derived: sum of 4 quarters · filed 2017-03-16 |
| 2014-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $3.40M derived: sum of 2 quarters · filed 2017-03-16 | $3.36M derived: sum of 3 quarters · filed 2017-03-16 | -$2.25M 10-K · filed 2017-03-16 |
| 2014-09-30 | $650.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $612.00K derived: sum of 2 quarters · filed 2015-11-10 | -$5.00M 10-Q · filed 2015-11-10 | |
| 2014-06-30 | -$38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$5.65M 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | -$5.61M 10-Q · filed 2015-06-18 | |||
| 2013-12-31 | -$644.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |